"Octreotide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
| Descriptor ID |
D015282
|
| MeSH Number(s) |
D04.345.566.650 D12.644.641.650
|
| Concept/Terms |
SMS 201-995- SMS 201-995
- SMS 201 995
- SMS 201995
- SM 201-995
- SM 201 995
- SM 201995
- Sandoz 201-995
- Sandoz 201 995
- Sandoz 201995
- Compound 201-995
- Compound 201 995
- Compound 201995
- SAN 201-995
- SAN 201 995
- SAN 201995
|
Below are MeSH descriptors whose meaning is more general than "Octreotide".
Below are MeSH descriptors whose meaning is more specific than "Octreotide".
This graph shows the total number of publications written about "Octreotide" by people in this website by year, and whether "Octreotide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2009 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Octreotide" by people in Profiles.
-
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 06 29; 403(10446):2807-2817.
-
Octreotide's role in the management of post-esophagectomy chylothorax. Dis Esophagus. 2024 Jun 01; 37(6).
-
Alpha-emitter therapy for pediatric relapsed metastatic pancreatic neuroendocrine tumor. Pediatr Blood Cancer. 2024 Jun; 71(6):e30961.
-
Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clin Cancer Res. 2024 02 16; 30(4):680-686.
-
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. Trials. 2024 Jan 16; 25(1):58.
-
A radiomic- and dosiomic-based machine learning regression model for pretreatment planning in 177 Lu-DOTATATE therapy. Med Phys. 2023 Nov; 50(11):7222-7235.
-
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst. 2023 09 07; 115(9):1001-1010.
-
Co-administration with A1M does not influence apoptotic response of 177Lu-octreotate in GOT1 neuroendocrine tumors. Sci Rep. 2023 04 19; 13(1):6417.
-
Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis. Ann Surg Oncol. 2022 May; 29(5):3072-3084.
-
External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy. JAMA Netw Open. 2022 01 04; 5(1):e2144170.